Erasca's pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial
ERAS•Erasca said its experimental pill ERAS-0015 shrank tumors in 44% of 25 pancreatic cancer patients taking a 32 mg daily dose, and 69% of patients with the two most common genetic variations. In lung cancer, 60% of five patients responded; Erasca plans to start late-stage trials in both cancers in 2027.
1. Trial responses
Erasca said its experimental cancer pill ERAS-0015 shrank tumors significantly in 44% of 25 patients with pancreatic cancer who took a 32 mg daily dose. Among patients with the two most common genetic variations of the disease, the response rate was 69%. In lung cancer, 60% of five patients who had previously received immunotherapy and chemotherapy responded.
2. Safety and next steps
The company said the treatment was generally well tolerated, but had earlier reported one death from lung inflammation in a patient taking a 24 mg dose. Erasca plans to start late-stage trials in pancreatic and lung cancers in 2027 and test ERAS-0015 alongside another experimental treatment, ERAS-4001, starting that year.




